CABA — Cabaletta Bio, Inc.
Is CABA overbought or oversold? Here is the current MarketMoodz read.
Cabaletta Bio, Inc. (CABA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.11. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.11
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Cabaletta Bio, Inc. (CABA) is an early-stage clinical biotech with meaningful upside tied to discrete clinical and corporate catalysts but faces substantial execution and funding risk. The current market backdrop favors growth on positive news but also shows investor preference for larger, defensive pharma, which could limit sustained inflows absent material data or partnerships. Key near-term drivers are clinical readouts, financing visibility and any business-development activity; downside remains significant if trials or funding go awry.
Key factors
- Early-stage clinical-stage biotech with a focused T-cell receptor / cell therapy pipeline that offers high upside if clinical data are positive
- Limited public disclosures and no recent EDGAR analysis provided, increasing uncertainty around near-term milestones and cash runway
- Market environment showing risk-on sentiment and growth flows, which can help small-cap biotech on positive news but favors larger, defensive pharma in current sector rotation
- Potential near-term catalysts include clinical data readouts, partnerships/licensing, or business development that could re-rate the stock
- Capital markets dynamics in biotech (convertible debt, dilution risk) and access to non-dilutive financing channels will materially affect shareholder value
Risks
- Clinical trial setbacks or negative data can cause steep share-price declines given binary nature of early-stage assets
- High likelihood of future dilution from equity raises or convertible financings to fund operations
- Limited liquidity and small market cap increase volatility and trading spreads
- Regulatory delays or adverse feedback from regulators on development programs
- Competition from larger cell- and gene-therapy developers with deeper pockets and more advanced pipelines
- Adverse macro/sector moves (rotation into large-cap defensive pharma) could reduce investor interest in speculative biotech names
- Execution risk in manufacturing, trial enrollment, and commercialization strategy for any partnered products
See today's live rating, score and targets
Members see the live hourly rating for CABA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.